Bristol-Myers Suspends Hepatitis C Drug Study on 'Serious' Issue - Wall Street Journal

InPharm

Bristol-Myers Suspends Hepatitis C Drug Study on 'Serious' Issue Wall Street Journal By SAABIRA CHAUDHURI And PETER LOFTUS · Bristol-Myers Squibb Co. has suspended its study of a drug intended to treat liver disease hepatitis C after a patient suffered heart failure. The move raises questions about the drug's potential and the $2.5 ... Bristol-Myers Suspends Hepatitis C Drug Clinical TrialBusinessweek Bristol-Myers Halts Hepatitis C Study on Safety IssueFox Business Bristol-Myers suspends hepatitis C treatment studyThe Seattle Times FierceBiotech all 100 news articles »